Skip to main content
. 2024 Jun 20;17:170. doi: 10.1186/s13104-024-06820-w

Fig. 1.

Fig. 1

Results for activity concentration, SUVbw, SUL, and TLG for Liraglutide (N = 17) and placebo (N = 13) (scan 2) for COPD exacerbations (N = 2) and controls (N = 3) (no known pulmonary disease)